Xynomic Pharma, a Raleigh-Shanghai clinical stage oncology company, has dosed the first patient in a Phase I/II trial that combines its lead drug, abexinostat, with Imbruvica (ibrutinib), a Janssen BTK inhibitor. The combination will be tested in patients with relapsed/refractory mantle cell lymphoma or relapsed/refractory diffuse large B-cell lymphoma at Memorial Sloan Kettering Cancer Center. Imbruvica is already approved for these indications. Abexinostat is a novel HDAC inhibitor in global pivotal trials against NHL and renal cell carcinoma.
Source: China Biotoday
